So far, no strong data suggests that people with psychiatric conditions respond differently to GLP-1s, says Samantha Catanzano, PharmD, a psychiatric pharmacist at UT Health Austins Bipolar Disorder Center in Texas
Every product is backed by 200+ published NABL lab reports, manufactured in FSSAI-certified, TV India GMP facilities, and tested for purity by independent third-party laboratories
Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes
In two rigorous 52-week studies, participants receiving tirzepatide experienced about 27-30 fewer sleep apnea events per hour, compared to only 5-6 fewer events in the placebo group
Understanding the Role of GLP-1 Medicines in Managing Type 2 Diabetes This animated video is designed for patients with type 2 diabetes
As a result, payers are seeking cost-effective alternatives that address the root causes of these conditions and promote sustainable behavior change